Delving into the Latest Updates on Nuclear New Biomedical (Changchun) Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Chemical drugs

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	2
Nervous System Diseases	1
Immune System Diseases	1
Infectious Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1
Chemical drugs	1

Top 5 Target	Count

PARP(Poly (ADP-Ribose) polymerase)	1

Part 1剂量递增和回填阶段主要目的：评价XY003治疗晚期实体瘤的安全性、耐受性，并确定最大耐受剂量（MTD）。次要目的：评价XY003在晚期实体瘤患者中单次给药和多次给药的药代动力学（PK）特征，通过12导联心电图评估XY003对QT/QTc间期的影响；评价XY003在晚期实体瘤患者中的初步有效性。 Part 2（剂量扩展阶段）主要目的：进一步评价XY003治疗HRD或NHEJ缺陷等DNA损伤修复缺陷晚期实体瘤的安全性和初步有效性，并确定II期推荐剂量（RP2D）。次要目的：评价XY003在HRD或NHEJ缺陷等DNA损伤修复缺陷的晚期实体瘤患者的药代动力学（PK）特征。

[Translation]

Part 1 (Dose Escalation and Refill Phase) Primary Objective: To evaluate the safety and tolerability of XY003 in treating advanced solid tumors and to determine the maximum tolerated dose (MTD). Secondary Objective: To evaluate the pharmacokinetic (PK) characteristics of XY003 in patients with advanced solid tumors after single and multiple doses; to assess the effect of XY003 on the QT/QTc interval using 12-lead electrocardiography; and to evaluate the preliminary efficacy of XY003 in patients with advanced solid tumors. Part 2 (Dose Expansion Phase) Primary Objective: To further evaluate the safety and preliminary efficacy of XY003 in treating advanced solid tumors with DNA damage repair deficiencies such as HRD or NHEJ deficiency, and to determine the Phase II recommended dose (RP2D). Secondary Objective: To evaluate the pharmacokinetic (PK) characteristics of XY003 in patients with advanced solid tumors with DNA damage repair deficiencies such as HRD or NHEJ deficiency.

Start Date-

Sponsor / Collaborator

Nuclear New Biomedical (Changchun) Co., Ltd.

100 Clinical Results associated with Nuclear New Biomedical (Changchun) Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Nuclear New Biomedical (Changchun) Co., Ltd.

Login to view more data

100 Deals associated with Nuclear New Biomedical (Changchun) Co., Ltd.

Login to view more data

100 Translational Medicine associated with Nuclear New Biomedical (Changchun) Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 27 Jun 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

Phase 1

Login to view more data